ASX · PTX.AX
Prescient Therapeutics Limited
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
Loading market information…
ASX · NXS.AX · AUD
Stock price, dividends, earnings
Quote as of Dec 31, 2025, 02:45 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Next Science Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Next Science Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Next Science Limited operates as an innovative medical technology company, committed to researching, developing, and commercializing advanced solutions that combat the detrimental effects of biofilms on human health in both the United States and Australia. The firm's product development is underpinned by its proprietary Xbio Technology platform. Its diverse portfolio includes SURGX, an antimicrobial gel designed for managing surgical infections; BACTISURE, a specialized wound lavage formulated to eliminate biofilm; BlastX, an antimicrobial wound gel that not only eradicates bacteria but also guards against recolonization, all while sustaining a moist healing environment; and XPERIENCE, a convenient, no-rinse antimicrobial solution aimed at preventing surgical site infections. Established in 2012, Next Science Limited is headquartered in Chatswood, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 |
|---|
| Aug 25, 2022 |
| -A$0.04-33.39% vs estimate |
| A$7.52M-7.29% vs estimate |
| Q4 2021 | Feb 23, 2022 | -A$0.04-22.83% vs estimate | A$6.88M-38.39% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.05-A$0.00 (-3.64%)
Prescient Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.6% below the high.
A$0.02+A$0.00 (+6.25%)
AnteoTech Limited’s quoted price sits in the lower half of its reported 52-week range, 65.31% below the high.
A$0.15A$0.00 (0.0%)
Nova Eye Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 26.83% below the high.
A$0.04A$0.00 (0.0%)
Emyria Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
A$0.04A$0.00 (0.0%)
Microba Life Sciences Limited’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
A$0.14A$0.00 (0.0%)
INOVIQ Ltd’s quoted price sits in the lower half of its reported 52-week range, 76.11% below the high.
A$0.04-A$0.00 (-2.22%)
IDT Australia Limited’s quoted price sits in the lower half of its reported 52-week range, 29.03% below the high.
A$0.06+A$0.00 (+7.14%)
Little Green Pharma Ltd’s quoted price sits in the lower half of its reported 52-week range, 57.14% below the high.
